Inventiva (IVA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$41,724.80

Revenue (quarter)

$22,834.00

Revenue growth (year over year)

−99.56%

Gross profit (trailing twelve months)

$41,724.80

Gross margin

100.00%

Net income (trailing twelve months)

−$287.9M

Net income (quarter)

−$79.3M

Net income growth (year over year)

+61.69%

Net margin

−690030.19%

Return on equity

−1012.41%

EPS (trailing twelve months)

−$0.61

Book value per share

$0.29

P/E (trailing twelve months)

—

Price to book

10.26

Debt to assets

76.51%

Payout ratio

—

Dividend yield

—

Company profile

Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs.

• Is Inventiva (IVA) profitable?

  No. Inventiva reported a net loss of $287.9M over the trailing twelve months.

• How much revenue does Inventiva (IVA) make?

  Inventiva generated $41,724.80 in revenue over the trailing twelve months, down 99.56% year over year.

• How do I buy stock in Inventiva (IVA)?

  IVA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.